As of July 2025, the global market for biologics Contract Development and Manufacturing Organizations (CDMOs) is on the precipice of a remarkable expansion, anticipated to reach USD 155 billion by 2034. Samsung Biologics, a key player in this dynamic industry, is actively solidifying its market position through strategic initiatives such as participation in high-profile industry events and the launch of innovative service offerings. Analysis reveals that the CDMO sector is characterized by rapid growth dynamics fueled by escalating global demand for biologics, advancements in therapeutic modalities, and a marked trend towards outsourcing manufacturing processes. Factors contributing to the sector's vitality include increasing complexity in biologic drug development and a shift in pharmaceutical companies seeking agile, efficient partners to streamline production operations.
Notably, at the 2025 BIO International Convention, Samsung Biologics leverages its traditional solo presence to enhance visibility amongst key stakeholders. The company’s large, digitally-equipped booth not only showcases its operational prowess but also introduces new developments such as multispecific antibody platforms and antibody-drug conjugate (ADC) services. The recent introduction of organoid-based Contract Research Organization (CRO) services emerges as a pivotal innovation that allows for deeper involvement in the early drug development stages, positioning Samsung Biologics favorably as an integrated partner for biotech firms, especially those still in preclinical stages.
Amid these advancements, the competitive landscape is substantially impacted by the rise of Chinese CDMOs, which are evolving from cost-centric options to innovators in their own right, marking a shift in market shares on a global scale. Additionally, the integration of AI into pharmaceutical processes continues to reshape operational methodologies, with a focus on balancing technological advancement with essential human insights. The ongoing trends point toward an evolving market characterized by specialization, collaboration, and a demand for agile production capabilities, all of which Samsung Biologics is strategically addressing.
The global Biologics Contract Development and Manufacturing Organization (CDMO) market was valued at USD 22.1 billion in 2024 and is projected to escalate rapidly, reaching approximately USD 50.2 billion by 2034, with a compound annual growth rate (CAGR) of 8.3% from 2025 onwards. Factors fueling this growth include the rising global demand for biologics, advances in therapeutic modalities, and an increasing inclination towards outsourcing biologics manufacturing. As pharmaceutical companies increasingly delegate the development, scale-up, and commercial production of biologic drugs—such as monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies—to CDMOs, this sector is positioned as a cornerstone of the modern pharmaceutical supply chain.
In the current landscape, leading CDMOs are expanding their service offerings to ensure a seamless, integrated production process. Notably, the integration of single-use technologies and digital analytics enables rapid production timelines while maintaining stringent quality standards. The COVID-19 pandemic has accentuated the need for agile, responsive manufacturing networks capable of scaling operations quickly, emphasizing the pivotal role of CDMOs in expeditious vaccine production.
To remain competitive and aligned with client requirements, CDMOs are evolving towards flexible, scalable service models. As a result, strategic partnerships with biotech firms are becoming more prevalent, fostering collaborative approaches that streamline project timelines and enable comprehensive end-to-end solutions.
Fill-and-finish services represent a crucial stage in the biologics manufacturing process, where bulk drug substances are transformed into market-ready products through aseptic processing. This sector is characterized as one of the highest-risk stages of sterile manufacturing, where contamination can jeopardize entire batches. Consequently, pharmaceutical companies specializing in innovative biologics or vaccines often lack the resources or expertise necessary to establish in-house aseptic manufacturing capabilities.
CDMOs like Adragos Pharma exemplify the essential role that fill-and-finish providers play, offering specialized facilities and the expertise required to handle these complex operations. Their services include not only aseptic processing but also comprehensive quality assurances to meet stringent regulatory requirements across various markets, including the US, Europe, and Asia. The industry trend is moving towards early engagement with CDMOs, promoting collaboration from the late preclinical or early Phase I stages to ensure optimal process design and effective risk management.
Recent insights indicate that early involvement with CDMOs can significantly mitigate complications, reducing timelines for bringing biologics to market. This ongoing collaboration advantages both the CDMO and pharmaceutical developers, establishing strategic partnerships that are essential in today’s rapidly evolving pharmaceutical landscape.
The demand for outsourced biologics manufacturing is driven by several factors, including the increasing complexity of biologics, the need for regulatory compliance, and the rising costs associated with developing in-house manufacturing capabilities. Biotech firms are increasingly outsourcing production to CDMOs to utilize their specialized technical expertise and established infrastructures, which can significantly lower both capital expenditures and operational risks.
Another critical driver is the preference for end-to-end service models, where clients seek comprehensive solutions that span from discovery through to commercialization. CDMOs are adapting by integrating services across the entire value chain, thereby consolidating manufacturing processes and aligning their capabilities with client needs. Such an approach not only optimizes resource allocation but also accelerates the product development timelines that are increasingly urgent in the modern market.
Moreover, as the market shifts towards personalized and orphan drugs, there is a growing necessity for flexible and scalable manufacturing solutions that can accommodate smaller batch sizes and complex molecules. The advancement of digital technologies, including automation and AI-driven analytics, is also shaping the operational landscape of CDMOs, enabling them to enhance process efficiencies and maintain high standards of quality control as they scale production for diverse product portfolios.
Samsung Biologics made a significant impact at the 2025 BIO International Convention, commonly referred to as BIO USA. Held from June 16 to 19, this event saw over 20,000 attendees and served as a critical platform for networking and showcasing the latest advancements in the biotechnology and pharmaceutical sectors. The company distinguished itself by maintaining a solo booth for the 13th consecutive year, highlighting its sustained commitment to engaging with an international audience within this competitive landscape. At this year's convention, Samsung Biologics occupied a strategic location near the entrance of the exhibition hall, utilizing a 167-square-meter booth equipped with advanced features like LED walls and interactive touchscreens. These installations were designed to dynamically present the company’s capabilities and innovations, such as its cutting-edge digital transformation strategies and the operational capacities of its recently inaugurated fifth production plant, which increased total production capacity to 784,000 liters—one of the largest in the industry. Moreover, the company used this platform to not only showcase its existing services but to also announce new offerings, including multispecific antibody development and an innovative antibody-drug conjugate (ADC) service. The overall approach aimed at solidifying its market share and enhancing brand visibility in the U.S. and beyond.
In a strategic move to expand its service portfolio, Samsung Biologics launched its organoid-based contract research organization (CRO) services during BIO USA 2025. This initiative marked a significant shift in the company’s traditional operations, allowing it to participate in the earlier stages of drug development, specifically the discovery phase. This new CRO service targets early-stage biotech companies, strengthening the company’s competitive edge by facilitating partnerships before these firms reach clinical stages. Executive Vice President Kevin Sharp highlighted that this service not only positions Samsung Biologics as a fully integrated partner but also opens avenues for potential collaborations in contract development and clinical trial partnerships. As of the first quarter of 2025, the company managed a substantial portfolio of 137 CDO contracts, reflecting its robust engagement with biotechs at various development stages, including those not yet disclosed for financial reasons. Notably, a memorandum of understanding (MOU) was established with LigaChem Biosciences to jointly develop multiple ADC candidates, illustrating Samsung Biologics' proactive approach in leveraging early-stage partnerships to enhance its capabilities in drug development.
Samsung Biologics has distinguished itself through its innovative production and development platforms that enable efficient biologics manufacturing. Among these, its strong focus on maintaining high-capacity production facilities, as illustrated by its Plant 5, plays a crucial role in meeting the evolving demands of the biologics market. The facility’s output capacity of 784,000 liters is not only a testament to the company’s infrastructural investments but also aligns with growing market requirements for scalable and flexible manufacturing solutions. Additionally, the company's strategic diversification into new modalities, such as mRNA, ADCs, and cell and gene therapies, showcases a forward-thinking approach that prepares it for shifts in the pharmaceutical landscape. The planned establishment of drug product and pre-filled syringe manufacturing capabilities for ADCs by 2027 further emphasizes its commitment to evolution in service offerings, addressing a wider range of client needs in a rapidly changing sector. By integrating digital transformation strategies, including AI-driven operations, Samsung Biologics aims to enhance operational efficiencies and strengthen its competitive positioning in an increasingly data-centric market.
The emergence of China as a formidable player in the global pharmaceutical landscape has dramatically reshaped competitive dynamics within the industry. Once primarily known as a hub for low-cost production, Chinese companies are now transitioning into significant contributors of innovation, quality, and high-value drug development. This shift is not a distant ambition—rather, it is manifesting in real-time as Chinese pharmaceutical contract development and manufacturing organizations (CDMOs) gain substantial market share against established Western giants. According to a recent report, by 2024, Chinese biopharma companies constituted 31% of the global drug development pipeline, increasingly leading in new drug candidates and innovative therapeutic modalities. Their ascent is driven by a combination of strategic government support, a rapidly expanding domestic market, and increased R&D investments, which together facilitate a robust environment for pharmaceutical innovation. As this trend continues, Western companies must navigate an evolving competitive landscape, reassessing their market strategies to compete with a rising wave of Chinese innovation.
As the integration of artificial intelligence (AI) into pharmaceuticals accelerates, the industry faces a critical junction in balancing technological capability with essential human connection. The insights from industry leaders, such as Cheryl Lubbert of Reverba Global, emphasize that while AI can handle data-intensive tasks and improve operational efficiency, it cannot replace the nuanced understanding required in patient and healthcare professional engagements. Effective communication and relationship building—critical for patient trust—cannot be automated. AI's role should complement the human touch rather than overshadow it, ensuring that empathetic engagement remains at the forefront of patient interactions. As pharmaceutical companies leverage AI-driven technologies, a clear strategy must emerge to harness these tools while safeguarding the empathetic aspects of healthcare.
With AI's deployment in clinical trials and patient insights, the risk arises of underrepresenting or disconnecting from diverse patient experiences, particularly among marginalized communities. This challenge underscores the necessity of maintaining human oversight and engagement strategies that prioritize trust and understanding, thereby enhancing the overall efficacy of clinical endeavors.
South Korea's government is actively fostering a comprehensive approach towards AI-driven drug development. As financial backing for pioneering AI initiatives grows, projections indicate a rapid expansion of the AI drug discovery market—from about USD 902.7 million in 2023 to an anticipated USD 2.89 billion by 2028. This effort includes significant investments aimed at developing capabilities for AI-enabled preclinical modeling and advancing antibody-based 'biobetter' drugs, enhancing both efficacy and convenience in treatment options. A key focus of this initiative is the establishment of strong partnerships with global technology players and the development of proprietary AI platforms aimed at facilitating drug candidate identification.
However, while South Korea's ambitions are commendable, local players still face considerable challenges, with many companies struggling with insufficient funding and operating deficits. The journey from aspirational growth to practical success in drug development requires not only financial investment but also an ecosystem that supports innovation alongside robust clinical insights. As the AI sector evolves, South Korea's strategic positioning within the global pharmaceutical industry will hinge on its ability to attract talent, enhance collaborative research synergies, and translate AI insights into actionable therapeutic breakthroughs.
Samsung Biologics is actively participating in the 2025 BIO International Convention, also known as BIO USA, which is being held from June 16 to 19, 2025. This event is regarded as the largest biotech and pharmaceutical trade show globally, drawing in over 20,000 industry professionals. As the only Korean company maintaining a dedicated booth at the event for 13 consecutive years, Samsung aims to bolster its global brand presence, especially in light of its Chinese competitor, Wuxi Biologics, opting not to participate for the second consecutive year. At BIO USA 2025, Samsung is setting up a prominent 167-square-meter booth, strategically positioned near the entrance of the exhibition hall to maximize foot traffic. The booth is designed using digital technology, including LED walls and interactive touchscreens, to showcase the company's latest capabilities and emphasize its strengths in contract development and manufacturing (CDMO). This approach is pivotal for engaging potential clients and partners, positioning Samsung as a leading player in the global CDMO market.
In an effort to diversify its service offerings, Samsung Biologics recently launched an organoid-based Contract Research Organization (CRO) service. This initiative is pivotal for early-stage drug discovery and aims to enhance the company’s engagement with biotech firms whose pipelines are in development. Kevin Sharp, the Executive Vice President, highlighted the importance of this new service, as it allows Samsung to enter the drug development process at an earlier stage than before, which is expected to unlock new client partnerships. The organoid platform positions Samsung as a fully integrated partner that provides end-to-end solutions, catering to both existing and potential clients. As of early 2025, the company is managing 137 Contract Development and Operations (CDO) contracts, many with early-stage biotech firms, thus demonstrating its proactive approach in establishing itself in the foundational phases of drug development.
Samsung Biologics is strategically targeting early-stage biotechnology companies and branching out to larger multinational pharmaceutical corporations. The integration of its new organoid-based CRO services is part of a broader commercial strategy aimed at increasing its service portfolio to meet diverse market demands, including antibody-drug conjugates (ADCs) and gene therapies. The ambitions of Samsung Biologics are reflected in their operational expansions, particularly through sales offices located in key markets such as New Jersey, Boston, and Tokyo. These offices facilitate continuous client engagement across time zones, ensuring seamless support. The company is not only focusing on the top 20 pharmaceutical clients but is also actively seeking relationships within the broader top 40, indicating a significant outreach effort aimed at reinforcing its presence and competitive edge within the global CDMO landscape.
According to recent analyses, the global biologics CDMO market is projected to experience significant growth over the next decade, with an anticipated value of USD 50.2 billion by 2034. This projection aligns with a compound annual growth rate (CAGR) of approximately 8.3%, which indicates a robust demand for CDMO services, driven predominantly by the increasing complexity and specialization of biologics. Outsourcing is expected to continue as biotech and pharmaceutical companies seek to mitigate capital risk and streamline their operations by leveraging the expertise and infrastructure of CDMOs.
In this evolving landscape, Samsung Biologics stands poised to capitalize on these trends. The company’s strategic investments in modular manufacturing facilities and advanced process technologies are designed to meet the impending surge in demand for biologics, particularly in therapeutic areas that require personalized treatments and complex biologics such as antibody-drug conjugates and cell therapies.
A key innovation area for CDMOs, including Samsung Biologics, is the integration of advanced technologies such as organoid models and artificial intelligence (AI). Organoid technology allows for more accurate modeling of human diseases, thereby facilitating the development and testing of biologics in a more physiologically relevant environment. This is expected to enhance predictability in clinical outcomes and streamline the development process.
Furthermore, AI is playing a transformative role along the entire pharmaceutical development pipeline, from drug discovery to clinical trials. Samsung Biologics is expected to invest heavily in AI-driven analytics and automation platforms, which can analyze large data sets more effectively than human efforts alone. For instance, as highlighted in recent publications, the global AI drug discovery market is projected to grow significantly, with South Korea increasing its investment in AI-driven drug development. Such technological progress is likely to reshape how CDMOs execute their research and development strategies, leading to faster and more efficient drug manufacturing cycles.
As Samsung Biologics focuses on expanding its research and development (R&D) pipeline, the implications of emerging technologies as highlighted indicate significant opportunities for growth. Investments in areas such as organoid modeling and AI applications are not simply enhancements; they are foundational to developing next-generation biologics. The company's future R&D initiatives will likely emphasize collaboration with biotech firms to explore co-development agreements that integrate these advanced technologies into their service offerings.
The South Korean government's commitment to bolster AI-enabled drug development is expected to complement Samsung Biologics' focus on innovations, providing a conducive policy environment that stimulates R&D investments. The anticipated rise in AI-driven solutions is particularly critical as CDMOs prepare to manage the complexities of biologic pipelines, which are becoming more diversified and specialized. This paradigm shift in developing robust biologic therapies aligns with global trends aiming to create efficient, effective, and patient-centered treatment options.
In the fast-evolving landscape of the CDMO market, Samsung Biologics stands poised for significant growth as it navigates the anticipated global expansion projected to exceed USD 155 billion by 2034. The company’s efforts in showcasing its innovations at BIO USA, alongside the launch of organoid-based CRO services, underline its commitment to leading in the integration of advanced technologies and meeting the demands of the rapidly shifting market. Key insights emphasize that continuous adaptation and technological differentiation are paramount to maintaining a competitive edge in biomanufacturing.
Looking ahead, Samsung Biologics has an opportunity to further bolster its strategic positioning by deepening R&D investments, particularly in organoid technologies and genetic editing processes that are gaining traction in the industry. Strengthening partnerships in key emerging markets, coupled with enhanced capabilities in data-driven manufacturing, will empower the company not only to retain its leadership but also to accelerate the development of next-generation biologics. As the landscape evolves, maintaining a focus on both technological advancements and strategic outreach will be essential in fostering patient-centric therapies and sustaining long-term growth.
As Samsung Biologics moves into the next phase of its strategic evolution, the emphasis should remain on leveraging synergies within its expanding operational framework while embracing global trends that shape the biopharma sector. The ongoing dedication to innovation, operational excellence, and strategic partnerships will not only ensure the company's relevance but also reinforce its role as a frontier leader in the global biologics CDMO market.